DE2922670A1 - Chewable compsn. for treating oral and respiratory disorders - contains active ingredients and opt. surfactants in chewable matrix - Google Patents

Chewable compsn. for treating oral and respiratory disorders - contains active ingredients and opt. surfactants in chewable matrix

Info

Publication number
DE2922670A1
DE2922670A1 DE19792922670 DE2922670A DE2922670A1 DE 2922670 A1 DE2922670 A1 DE 2922670A1 DE 19792922670 DE19792922670 DE 19792922670 DE 2922670 A DE2922670 A DE 2922670A DE 2922670 A1 DE2922670 A1 DE 2922670A1
Authority
DE
Germany
Prior art keywords
chewable
active ingredients
surfactants
compsn
opt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19792922670
Other languages
German (de)
Other versions
DE2922670C2 (en
Inventor
Heinz-Joachim Dr Kinkel
Erich Robens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Battelle Institut eV
Original Assignee
Battelle Institut eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Battelle Institut eV filed Critical Battelle Institut eV
Priority to DE19792922670 priority Critical patent/DE2922670C2/en
Publication of DE2922670A1 publication Critical patent/DE2922670A1/en
Application granted granted Critical
Publication of DE2922670C2 publication Critical patent/DE2922670C2/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058—Chewing gums

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Chewable compsn. for treating diseases of the mouth, throat or respiratory tract comprises a chewable matrix (A) contg. active ingredients (B) and opt. surfactants. Pref. (B) are incorporated into finely-divided porous particles of size 0.1-100 mu m, esp. made of cellulose-contg. materials derived from cereal grains, starch, Al oxide of hydroxide, MgO, SiO2 and/or CaCO3. (B) are released at a uniform rate over a long period. The compsns. are sugar-free so do not induce caries and are acceptable to diabetics.

Description

Kaubare Arzneiform Chewable dosage form

Die Erfindung betrifft eine kaubare Arzneiform gegen Erkrankungen des Mund- und Rachenraumes und der Atemwege.The invention relates to a chewable medicinal form against diseases of the mouth and throat and the airways.

Zur Behandlung von Erkrankungen des Mund- und Rachenraumes und der Atemwege werden üblicherweise Lutschbonbons und Pastillen verwendet, denen nichtrezeptpflichtige Wirkstoffe, meist Pflanzenauszüge, beigefügt sind. Nachteilig bei dieser Arzneiform ist, daß die Matrix im wesentlichen aus Zucker besteht, der kariesfördernd ist und von zuckerkranken Personen nicht eingenommen werden kann. Ferner besteht bei den meisten Patienten die Neigung, solche Pastillen und Bonbons zu zerbeißen, wodurch die Applikationsdauer verringert und durch kurzzeitige Uberdosierung Schädigungen hervorgerufen werden können.For the treatment of diseases of the mouth and throat area and the Respiratory lozenges and lozenges are commonly used for those without a prescription Active ingredients, mostly plant extracts, are attached. Disadvantageous with this dosage form is that the matrix consists essentially of sugar, which is caries-promoting and cannot be taken by diabetic people. There is also the most patients have a tendency to chew such lozenges and candies, which leads to them the duration of application is reduced and short-term overdose causes damage can be evoked.

Der vorliegenden Erfindung liegt daher die Aufgabe zugrunde, eine Arzneiform zu entwickeln, die über einen längeren Zeitraum hinweg die Wirkstoffe möglichst gleichmäßig in den Mund- und Rachenraum abgibt.The present invention is therefore based on the object of a To develop drug form that over a longer period of time the active ingredients releases as evenly as possible into the mouth and throat.

Es hat sich nun gezeigt, daß sich diese Aufgabe in technisch fortschrittlicher Weise lösen läßt, wenn die Arzeiform aus einer kaubaren Matrix besteht, die medikamentöse Wirkstoffe und ggfs. oberflächenaktive Substanzen enthält. Die vorteilhaften Weiterbildungen der erfindungsgemäßen Arzneiform sind in den Unteransprüchen 2 bis 4 beschrieben.It has now been shown that this task is technically more advanced If the drug form consists of a chewable matrix, the drug-based one can be solved wisely Contains active ingredients and, if necessary, surface-active substances. The advantageous further training of the pharmaceutical form according to the invention are described in subclaims 2 to 4.

Als kaubare Matrizes werden an sich bekannte Substanzen herangezogen, z.B. hochmolekulare, natürliche oder künstliche Harze und Wachse, Kautschuk, Piccolit-Harz, Hartparaffine, Bienenwachs, Wollfett, Carnaubawachs, Walrat und Candellilawachs. Die Matrix kann auch übliche Zusatzstoffe enthalten, z.B. Geschmack- und Aromastoffe. Als Geschmackstoffe können Zuckeraustauschstoffe wie Sorbit, und Süßstoffe wie Saccharin, verwendet werden. Als Aromastoffe sind z.B. Pfefferminzöl, Spearmintöl, Anisöl, Eukalyptusöl, Gewürznelkenöl, Vanillearoma und Zimtaroma geeignet.Known substances are used as chewable matrices, e.g. high molecular weight, natural or artificial resins and waxes, rubber, piccolite resin, Hard paraffins, beeswax, wool fat, carnauba wax, whale rat and candellilla wax. The matrix can also contain conventional additives, e.g. flavorings and aromas. Sugar substitutes such as sorbitol and sweeteners such as saccharin, be used. The aromatic substances are e.g. peppermint oil, spearmint oil, anise oil, Eucalyptus oil, clove oil, vanilla flavor and cinnamon flavor are suitable.

Zur Erleichterung des Transports der Wirkstoffe und damit zur Steigerung ihrer Wirkung können der Kaumasse ferner Tenside zugeführt werden, die die Oberflächenspannung des erkrankten Gewebes herabsetzen. Solche magen- und darmverträglichen Tenside sind z.B. Natriumlaurylsulfat, Dinatriumoctylsulfo- succinat, Natriumalkylsulfoacetat, Natriumlaurylsarkosinat, Sorbitanester, Diammoniumphosphat, Borax, Glykokoll sowie enzymatisch wirkende Verbindungen.To facilitate the transport of the active ingredients and thus to increase Surfactants can also be added to their effect in the chewing mass, which reduce surface tension of the diseased tissue. Such gastrointestinal surfactants are e.g. sodium lauryl sulfate, disodium octyl sulfo- succinate, sodium alkyl sulfoacetate, Sodium lauryl sarcosinate, sorbitan ester, diammonium phosphate, borax, glycocolla as well enzymatically acting compounds.

Die kaubare Matrix enthält bis zu 1 %, vorzugsweise 0,2 bis 0,6 % medikamentöse Wirkstoffe; z.B. Salbeiöl gegen Verschleimung der Atemorgane, Ecchinacea-Extrakt zur Infektionshemmung, Thymol zur Desinfektion, Arnikaöl gegen Entzündungen der Mundschleimhaut, Azulen gegen Entzündungen der Schleimhäute und gegen Katarrhe, Trihydroxyäthylrutin gegen Husten, Rosmarinextrakt gegen Mundschleimhautentzündung sowie Ascorbinsäure zur lokalen Stoffwechselsteigerung.The chewable matrix contains up to 1%, preferably 0.2 to 0.6% active pharmaceutical ingredients; e.g. sage oil against mucus in the respiratory organs, ecchinacea extract for infection control, thymol for disinfection, arnica oil against inflammation of the Oral mucosa, azulene against inflammation of the mucous membranes and against catarrh, Trihydroxyäthylrutin against coughs, rosemary extract against inflammation of the oral mucosa as well as ascorbic acid to increase the local metabolism.

Die erfindungsgemäße Arzneiform kann in an sich bekannter Weise durch Verkneten der Bestandteile hergestellt werden.The pharmaceutical form according to the invention can be carried out in a manner known per se Knead the ingredients.

Zur Erzielung einer gleichmäßigen Dosierung während der Kauzeit sowie zur Reduktion der Wirkstoffabgaberaten können die Wirkstoffe in einer vorteilhaften Verarbeitungsform vor dem Kneten in feinteilige, poröse Teilchen eingelagert, vorzugsweise in anorganische Teilchen wie Aluminiumhydroxid, Aluminiumoxid, Magnesiumoxid, Siliciumdioxid und Calciumcarbonat oder in feingemahlene cellulosehaltige Gerüstsubstanzen aus Getreidekörnern oder Stärke. Die porösen Teilchen können z.B.To achieve an even dosage during the chewing time as well to reduce the active ingredient release rates, the active ingredients can be used in an advantageous manner Processing form incorporated into finely divided, porous particles before kneading, preferably into inorganic particles such as aluminum hydroxide, aluminum oxide, magnesium oxide, silicon dioxide and calcium carbonate or finely ground cellulose-containing structural substances Cereal grains or starch. The porous particles can e.g.

durch Tränken mit der Wirkstofflösung und anschließendem Entzug des Lösungsmittels durch Trocknen bzw. Verdampfen mit dem Wirkstoff beladen werden. Diese Beladung kann auch durch Verpressen des Wirkstoffpulvers mit dem Pulver aus porösen Teilchen und anschließendem Vermahlen des Preßlings erfolgen.by soaking in the active ingredient solution and then withdrawing the Solvent are loaded with the active ingredient by drying or evaporation. This loading can also be achieved by compressing the active ingredient powder with the powder porous particles and then grinding the compact.

Claims (4)

Patentansprüche 1. Kaubare Arzneiform gegen Erkrankungen des Mund- und Rachenraumes und der Atemwege, dadurch gekennzeichnet, daß sie aus einer kaubaren Matrix besteht, die medikamentöse Wirkstoffe und ggfs. oberflächenaktive Substanzen enthält. Claims 1. Chewable medicinal form against diseases of the oral and pharynx and the respiratory tract, characterized in that they consist of a chewable Matrix consists of active pharmaceutical ingredients and, if necessary, surface-active substances contains. 2. Arzneiform nach Anspruch 1, dadurch gekennzeichnet, daß die Wirkstoffe in feinteiligen porösen Teilchen mit einer Teilchengröße von 0,1 bis 100 um eingelagert sind.2. Pharmaceutical form according to claim 1, characterized in that the active ingredients embedded in finely divided porous particles with a particle size of 0.1 to 100 μm are. 3. Arzneiform nach Anspruch 1 und 2, dadurch gekennzeichnet, daß die porösen Teilchen aus cellulosehaltigen Gerüstbe- standteilen aus Getreidekörnern, Stärke, Aluminiumhydroxid, Aluminiumoxid, Magnesiumoxid, Siliciumdioxid und/oder Calciumcarbonat bestehen.3. Pharmaceutical form according to claim 1 and 2, characterized in that the porous particles made of cellulose-containing framework share out Cereal grains, starch, aluminum hydroxide, aluminum oxide, magnesium oxide, silicon dioxide and / or calcium carbonate. 4. Arzneiform nach einem der Ansprüche 1 bis 3, dadurch gekennzeichnet, daß als oberflächenaktive Stoffe Natriumlaurylsulfat, Dinatriumoctylsulfosuccinat, Natriumalkylsulfoacetat, Natriumlaurylsarkosinat, Sorbitanester, Diammoniumphosphat, Borax, Glykokol sowie enzymatisch wirkende Verbindungen verwendet werden.4. Pharmaceutical form according to one of claims 1 to 3, characterized in that that as surface-active substances sodium lauryl sulfate, disodium octyl sulfosuccinate, Sodium alkyl sulfoacetate, sodium lauryl sarcosinate, sorbitan ester, diammonium phosphate, Borax, Glykokol and enzymatically acting compounds can be used.
DE19792922670 1979-06-02 1979-06-02 Chewable dosage form Expired DE2922670C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19792922670 DE2922670C2 (en) 1979-06-02 1979-06-02 Chewable dosage form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19792922670 DE2922670C2 (en) 1979-06-02 1979-06-02 Chewable dosage form

Publications (2)

Publication Number Publication Date
DE2922670A1 true DE2922670A1 (en) 1980-12-11
DE2922670C2 DE2922670C2 (en) 1982-09-09

Family

ID=6072438

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19792922670 Expired DE2922670C2 (en) 1979-06-02 1979-06-02 Chewable dosage form

Country Status (1)

Country Link
DE (1) DE2922670C2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239541A2 (en) * 1986-03-27 1987-09-30 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
FR2608156A1 (en) * 1986-12-12 1988-06-17 Ethypharm Sa Chewing gum for releasing tobacco
EP0299923A2 (en) * 1987-07-13 1989-01-18 Warner-Lambert Company Anesthetic-containing chewing gum compositions
EP0299924A2 (en) * 1987-07-13 1989-01-18 Warner-Lambert Company Reduced base content chewing gum compositions having anesthetic properties
EP0399479A1 (en) * 1989-05-26 1990-11-28 Gerhard Dr. Gergely Chewing gum for the disinfection of the mouth and the throat and process for its preparation
US5332579A (en) * 1990-08-07 1994-07-26 Umbdenstock Anthony J Nutritional supplement for optimizing cellular health

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2435322A1 (en) * 1974-07-23 1976-02-12 Egwin Leiber Appts. measuring forces in structures - measuring body deformed by forces transmitted from one structural part to another
FR2320083A1 (en) * 1975-08-07 1977-03-04 Sigma Tau Ind Farmaceuti Medicated chewing gum - contg. e.g. cetylpyridinium chloride as antiseptic and pref. guaiazulene decongestant

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2435322A1 (en) * 1974-07-23 1976-02-12 Egwin Leiber Appts. measuring forces in structures - measuring body deformed by forces transmitted from one structural part to another
FR2320083A1 (en) * 1975-08-07 1977-03-04 Sigma Tau Ind Farmaceuti Medicated chewing gum - contg. e.g. cetylpyridinium chloride as antiseptic and pref. guaiazulene decongestant

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239541A2 (en) * 1986-03-27 1987-09-30 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
EP0239541A3 (en) * 1986-03-27 1987-12-23 Warner-Lambert Company Medicament adsorbates with surfactant and their preparation
FR2608156A1 (en) * 1986-12-12 1988-06-17 Ethypharm Sa Chewing gum for releasing tobacco
EP0299923A2 (en) * 1987-07-13 1989-01-18 Warner-Lambert Company Anesthetic-containing chewing gum compositions
EP0299924A2 (en) * 1987-07-13 1989-01-18 Warner-Lambert Company Reduced base content chewing gum compositions having anesthetic properties
EP0299923A3 (en) * 1987-07-13 1989-10-25 Warner-Lambert Company Anesthetic-containing chewing gum compositions
EP0299924A3 (en) * 1987-07-13 1989-10-25 Warner-Lambert Company Reduced base content chewing gum compositions having anesthetic properties
EP0399479A1 (en) * 1989-05-26 1990-11-28 Gerhard Dr. Gergely Chewing gum for the disinfection of the mouth and the throat and process for its preparation
US5332579A (en) * 1990-08-07 1994-07-26 Umbdenstock Anthony J Nutritional supplement for optimizing cellular health

Also Published As

Publication number Publication date
DE2922670C2 (en) 1982-09-09

Similar Documents

Publication Publication Date Title
DE69032982T2 (en) Compositions and methods for the manufacture of oral disintegrable medicines
DE69531788T2 (en) IMPROVED BIOADHESIVE PHARMACEUTICAL DELIVERY SYSTEM
DE68921463T2 (en) LOW MELTABLE, POWDERABLE MEDICINAL EXCIPIENT AND ITS USE IN RELATION TO PHARMACEUTICAL COMPOSITIONS.
DE3874250T2 (en) Anesthetic agents containing chewing gum compositions.
DE69532031T2 (en) MEDIA CONTAINING THYROID HORMONES
DE2611041C2 (en)
DE2332484C2 (en) Drugs with delayed release of active substances
DE69816440T2 (en) METHOD FOR PRODUCING FLURBIPROFEN-SUCKLING TABLETS
DE69326274T2 (en) Intraoral device with slow drug release
DE69615551T2 (en) USE OF A PREPARATION CONTAINING AMOXYCILLIN AND CLAVULANIC ACID FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING BACTERIAL INFECTIONS IN PEDIATRIC PATIENTS
DE19814256A1 (en) Solid, fast-breaking cetirizine formulations
EP0125634B1 (en) Use of a secretolytically active substance for the manufacture of a remedy against snoring and for combating snore phenomenon
WO1987004619A1 (en) Use of tannin agents and/or chlorogenic acid, foodstuffs, stimulants and/or medicines with the addition of tannin agents and/or chlorogenic acid
DE102017100042B4 (en) Active substance-loadable absorbent piece, pacifier and use of a dosage form in a pacifier
DE2922670C2 (en) Chewable dosage form
DE69016665T3 (en) ORAL S (+) - MEDIUM CONTAINING FLURBIPROFEN OR KETOPROFEN.
CH640731A5 (en) COATING AGENTS FOR SOLID MEDICATIONS.
EP0399479B1 (en) Chewing gum for the disinfection of the mouth and the throat and process for its preparation
DE3338978A1 (en) Verapamil and gallopamil and their physiologically tolerated salts for application onto the mucous membranes of the mouth, of the naso-pharyngeal space and of the rectum for absorption
DE2606533A1 (en) Xylitol for treatment of caries and pre-carious conditions - remineralises the tooth substance and reduces carious lesions (BE190876)
EP1135147B1 (en) Method for producing medicaments from plant extracts, in a solid form of administration
DE69902879T2 (en) VEGETABLE ANTIVIRAL AGENT
DE2922671C2 (en) Dental care and cleaning products
DE2062715B2 (en) PROCESS FOR THE MANUFACTURING OF ORAL ADMINISTRATIVE MEDICINAL PREPARATIONS WITH PROTRACTED DELIVERY OF ACTIVE SUBSTANCE AND MEDICINAL PREPARATION
AT414095B (en) Preparation useful e.g. to treat dry mucous membrane in oral and throat area comprises medical and/or food organic substance, flavor material, mucoadhesive substance, sugar (alcohol) and carrier substance e.g. fat and/or oil

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8363 Opposition against the patent
8330 Complete disclaimer